Cancer drug developer Felicitex files for proposed $16M IPO

Dec. 01, 2022 4:36 PM ETBy: Val Kennedy, SA News Editor

Large yellow signboard on metal frame with the word IPO

ismagilov

Felicitex Therapeutics (FLCT), which is developing therapies targeted at dormant cancer cells, has filed to raise around $16M through an initial public offering.

The biotech company said in a filing that it is considering offering 2.5M units priced

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.